Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Protagenic Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 11 | 11 | 0 |
| Shares | 537.5K | 159.8K | −377.7K (−70.3%) |
| Value | $205.6K | $145.7K | −$59.9K (−29.2%) |
New holders (2)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 26,598 | $24.4K | 0.00% |
| UBS Group AG | 10,078 | $9.12K | 0.00% |
Sold out (2)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Wells Fargo & Company | 27 | $47 |
| Eagle Asset Management Inc | 419,324 | – |